Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Idrs Labs Private Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and is located within 1 distinct art unit. Such a concentrated profile indicates that the company's current interactions with the patent office are extremely focused, with no diversification across different technical departments or examiner groups. The presence of a single art unit suggests a very specific technical niche for the underlying application and requires a highly targeted legal approach.
Nizal S Chandrakumar is the busiest examiner for this portfolio. This examiner manages the company's total pending workload at this time. Because there is only 1 distinct examiner involved, the success of the current prosecution cycle depends entirely on the specific tendencies and requirements of this individual. Practitioners should focus on the specific history of this examiner within the Biotechnology & Pharmaceuticals sector to anticipate potential hurdles. The lack of multiple pending actions means every response to this examiner is critical for the company's immediate patent goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18310501 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN | CHANDRAKUMAR, NIZAL S | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18310501 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN | CHANDRAKUMAR, NIZAL S | 76d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18310501 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | 76d | Pending | May 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIdrs Labs Private Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Idrs Labs Private Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
